Condition
Castrate Sensitive Prostate Cancer
Total Trials
4
Recruiting
2
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Recruiting2
Active Not Recruiting2
Clinical Trials (4)
Showing 4 of 4 trials
NCT06429813Not ApplicableRecruitingPrimary
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
NCT03860987Phase 2Active Not RecruitingPrimary
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
NCT04748042Phase 2Active Not Recruiting
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
NCT06652607Recruiting
PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer
Showing all 4 trials